Duloxetine Capsule, Delayed Release
Product Images NDC 68071-3775

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68071-3775). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3775 9)

The text provides detailed information about Duloxetine 60mg capsules, including composition details, manufacturer information, and expiration dates. It also mentions a warning to keep the medication out of reach of children and to store it at a controlled temperature of 68-77°F. It advises contacting a doctor for medical advice and reporting any side effects to the FDA.*

FDA Label Image

Structure (69d6387b 794f 415d 8013 23cca0a6984f 01)

FDA Label Image

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 02)

The text provides information on the proportion of patients with relapse under treatment with placebo and duloxetine over a certain time period. It includes a chart showing the time from randomization to relapse in days, likely using the Kaplan-Meier estimator method.*

FDA Label Image

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 03)

This data provides the proportion of patients with relapse in a study comparing a placebo group to a group treated with duloxetine over a period of time. The graph shows the time in days from randomization to relapse for patients using the Kaplan-Meier estimator method.*

FDA Label Image

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 04)

This text provides information on the percentage of patients improved with different doses of Duloxetine and a placebo. It also includes data on the percent improvement in pain from the baseline. This information can be used to evaluate the effectiveness of different treatments in managing pain.*

FDA Label Image

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 05)

This is a comparison showing the percentage of patients improved based on the percent improvement in pain from baseline when taking Duloxetine 60 mg twice a day, Duloxetine 60 mg once a day, and Placebo. The data may be part of a clinical trial or study evaluating the effectiveness of these different treatment regimens.*

FDA Label Image

Fig 5 (69d6387b 794f 415d 8013 23cca0a6984f 06)

FDA Label Image

Fig 6 (69d6387b 794f 415d 8013 23cca0a6984f 07)

This document provides information on the percentage of patients who improved with different doses of Duloxetine and Placebo in a pain management study. The chart shows the level of improvement in pain experienced by patients compared to their baseline pain levels. The data indicate the effectiveness of Duloxetine at different doses in managing pain symptoms.*

FDA Label Image

Fig 7 (69d6387b 794f 415d 8013 23cca0a6984f 08)

This is a detailed figure showing the percentage of pediatric patients aged 13 to 17 years old with Juvenile Fibromyalgia Syndrome, achieving various levels of pain relief at week 12 in Study FM-4. The graph compares the pain relief between Duloxetine 60mg Once Daily and Placebo. The percentage of patients improved is represented along the y-axis, and the percent improvement in pain from baseline is shown along the x-axis. Pain relief was measured by the Brief Pain Inventory - Modified short Form: Adolescent Version Average Pain Score. Duloxetine-treated patients started with 30 mg once daily for 1 week and then titrated to 60 mg once daily for 12 weeks.*

FDA Label Image

Figure 8 (69d6387b 794f 415d 8013 23cca0a6984f 09)

This description provides data on the percentage of patients who experienced improvement in pain from baseline while undergoing treatment with either a placebo or Duloxetine at 60/120 mg once daily. The graph shows the scale of improvement in pain, ranging from 0 to 100%, with the corresponding data points for each treatment option.*

FDA Label Image

Figure 9 (69d6387b 794f 415d 8013 23cca0a6984f 10)

This text provides information on the percentage of patients improved with placebo and Duloxetine 60 mg once daily. It also shows the percentage improvement in pain from baseline using the BOCF method.*

FDA Label Image

Figure 10 (69d6387b 794f 415d 8013 23cca0a6984f 11)

This text provides information about the percentage of patients who showed improvement with Duloxetine 60/120 mg compared to a placebo. The chart shows a 100% improvement with Duloxetine, and the percentage improvement in pain from the baseline is measured. The numbers on the chart range from 10 to 90, indicating levels of improvement. The data suggests that Duloxetine has a significant impact on pain relief.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.